#,ama,title,journal,year,volume,issue,pages,doi,pmid,authors
1," Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2019;None.","Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease",Global Initiative for Chronic Obstructive Lung Disease (GOLD),2019,,,,,,
2,"Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187.",Chronic bronchitis and chronic obstructive pulmonary disease,Am J Respir Crit Care Med,2013,187,,,,,Kim V; Criner GJ
3, Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema. Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema. 2017;None.,Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema,Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema,2017,,,,,,
4,"Sherman CB, Xu X, Speizer FE. Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis. 1992;146.",Longitudinal lung function decline in subjects with respiratory symptoms,Am Rev Respir Dis,1992,146,,,,,Sherman CB; Xu X; Speizer FE
5,"Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153.",Association of chronic mucus hypersecretion with FEV 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group,Am J Respir Crit Care Med,1996,153,,,,,Vestbo J; Prescott E; Lange P
6,"Guerra S, Sherrill DL, Venker C. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009;64.",Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk,Thorax,2009,64,,,,,Guerra S; Sherrill DL; Venker C
7,"Seemungal TA, Donaldson GC, Paul EA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157.",Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease,Am J Respir Crit Care Med,1998,157,,,,,Seemungal TA; Donaldson GC; Paul EA
8,"Kim V, Garfield JL, Grabianowski CL. The effect of chronic sputum production on respiratory symptoms in severe COPD. COPD. 2011;8.",The effect of chronic sputum production on respiratory symptoms in severe COPD,COPD,2011,8,,,,,Kim V; Garfield JL; Grabianowski CL
9,"De Oca MM, Halbert RJ, Lopez MV. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J. 2012;40.",The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study,Eur Respir J,2012,40,,,,,De Oca MM; Halbert RJ; Lopez MV
10,"Burgel PR, Nesme-Meyer P, Chanez P. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135.",Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects,Chest,2009,135,,,,,Burgel PR; Nesme-Meyer P; Chanez P
11,"Kim V, Han MK, Vance GB. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140.",The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study,Chest,2011,140,,,,,Kim V; Han MK; Vance GB
12,"Lange P, Nyboe J, Appleyard M. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax. 1990;45.",Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes,Thorax,1990,45,,,,,Lange P; Nyboe J; Appleyard M
13,"Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995;8.",Chronic mucus hypersecretion in COPD and death from pulmonary infection,Eur Respir J,1995,8,,,,,Prescott E; Lange P; Vestbo J
14,"Pelkonen M, Notkola IL, Nissinen A. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest. 2006;130.",Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men,Chest,2006,130,,,,,Pelkonen M; Notkola IL; Nissinen A
15,"Coad JE, Bischof JC. Histologic differences between cryothermic and hyperthermic therapies. Thermal Treatment of Tissue: Energy Delivery and Assessment II. 2003;4954. doi:10.1117/12.476334.",Histologic differences between cryothermic and hyperthermic therapies,Thermal Treatment of Tissue: Energy Delivery and Assessment II,2003,4954,,,10.1117/12.476334,,Coad JE; Bischof JC
16,"Godwin BL, Coad JE. Healing responses following cryothermic and hyperthermic tissue ablation. Thermal Treatment of Tissue: Energy Delivery and Assessment. 2009;7181. doi:10.1117/12.811252.",Healing responses following cryothermic and hyperthermic tissue ablation,Thermal Treatment of Tissue: Energy Delivery and Assessment,2009,7181,,,10.1117/12.811252,,Godwin BL; Coad JE
17,"Mulcahey TI, Coad JE, Fan WL. Metered Cryospray TM : a novel uniform, controlled, and consistent in vivo application of liquid nitrogen cryogenic spray. Med Devices. 2017;10.","Metered Cryospray TM : a novel uniform, controlled, and consistent in vivo application of liquid nitrogen cryogenic spray",Med Devices,2017,10,,,,,Mulcahey TI; Coad JE; Fan WL
18,"Slebos DJ, Breen D, Coad J. Safety and histological effect of liquid nitrogen metered spray cryotherapy in the lung. Am J Respir Crit Care Med. 2017;196. doi:10.1183/13993003.00556-2020.",Safety and histological effect of liquid nitrogen metered spray cryotherapy in the lung,Am J Respir Crit Care Med,2017,196,,,10.1183/13993003.00556-2020,,Slebos DJ; Breen D; Coad J
19,"Krimsky WS, Broussard JN, Sarkar SA. Bronchoscopic spray cryotherapy: assessment of safety and depth of airway injury. J Thorac Cardiovasc Surg. 2010;139.",Bronchoscopic spray cryotherapy: assessment of safety and depth of airway injury,J Thorac Cardiovasc Surg,2010,139,,,,,Krimsky WS; Broussard JN; Sarkar SA
20,"Jones PW, St. George's Respiratory Questionnaire: MCID. COPD. 2005;2.",George's Respiratory Questionnaire: MCID,COPD,2005,2,,,,,Jones PW; St
21,"Puhan MA, Chandra D, Mosenifar Z. The minimal important difference of exercise tests in severe COPD. Eur Respir J. 2011;37.",The minimal important difference of exercise tests in severe COPD,Eur Respir J,2011,37,,,,,Puhan MA; Chandra D; Mosenifar Z
22,"Kon SS, Canavan JL, Jones SE. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2.",Minimum clinically important difference for the COPD Assessment Test: a prospective analysis,Lancet Respir Med,2014,2,,,,,Kon SS; Canavan JL; Jones SE
23,"Raj AA, Pavord DI, Birring SS. Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire?. Handb Exp Pharmacol. 2009;187.",Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire?,Handb Exp Pharmacol,2009,187,,,,,Raj AA; Pavord DI; Birring SS
24,"Kim V, Zhao H, Regan E. George's Respiratory Questionnaire definition of chronic bronchitis may be a better predictor of COPD exacerbations compared with the classic definition. Chest. 2019;156.",George's Respiratory Questionnaire definition of chronic bronchitis may be a better predictor of COPD exacerbations compared with the classic definition,Chest,2019,156,,,,,Kim V; Zhao H; Regan E
25,"Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7.",Lung function decline in COPD,Int J Chron Obstruct Pulmon Dis,2012,7,,,,,Tantucci C; Modina D
26,"Wallace AE, Kaila S, Bayer V. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25.",Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population,J Manag Care Spec Pharm,2019,25,,,,,Wallace AE; Kaila S; Bayer V
27,"Donaldson GC, Seemungal TA, Patel IS. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J. 2003;22.","Longitudinal changes in the nature, severity and frequency of COPD exacerbations",Eur Respir J,2003,22,,,,,Donaldson GC; Seemungal TA; Patel IS
28,"Müllerova H, Gelhorn H, Wilson H. St George's Respiratory Questionnaire score predicts outcomes in patients with COPD: analysis of individual patient data in the COPD Biomarkers Qualification Consortium Database. Chronic Obstr Pulm Dis. 2017;4.",St George's Respiratory Questionnaire score predicts outcomes in patients with COPD: analysis of individual patient data in the COPD Biomarkers Qualification Consortium Database,Chronic Obstr Pulm Dis,2017,4,,,,,Müllerova H; Gelhorn H; Wilson H
29,"Van Der Molen T, Miravitlles M, Kocks JW. COPD management: role of symptom assessment in routine clinical practice. Int J Chron Obstruct Pulmon Dis. 2013;8.",COPD management: role of symptom assessment in routine clinical practice,Int J Chron Obstruct Pulmon Dis,2013,8,,,,,Van Der Molen T; Miravitlles M; Kocks JW
30,"Valipour A, Ing A, Williamson J. Late breaking abstractfirst-in-human results of bronchial rheoplasty: an endobronchial treatment for chronic bronchitis (CB). Eur Respir J. 2018;52:2162.",Late breaking abstractfirst-in-human results of bronchial rheoplasty: an endobronchial treatment for chronic bronchitis (CB),Eur Respir J,2018,52,,2162,,,Valipour A; Ing A; Williamson J
31,"Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;7:1287.",Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease,Cochrane Database Syst Rev,2015,7,,1287,,,Poole P; Chong J; Cates CJ
32,"Herath SC, Normansell R, Maisey S. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;10:9764.",Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD),Cochrane Database Syst Rev,2018,10,,9764,,,Herath SC; Normansell R; Maisey S
33,"Oba Y, Keeney E, Ghatehorde N. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018;12:12620. doi:10.1183/13993003.00556-2020.",Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis,Cochrane Database Syst Rev,2018,12,,12620,10.1183/13993003.00556-2020,,Oba Y; Keeney E; Ghatehorde N
